Predictors of airway obstruction in HIV-infected subjects.

<p>Note: HAART = highly active antiretroviral therapy.</p

Characteristics of HIV-infected subjects according to use of HAART.

<p>Note: BP = bacterial pneumonia; CI = confidence interval; HAART = highly active antiretroviral therapy; IDU = intravenous drug use; MSM = men who have sex with men; OR = odds ratio; PCP = <i>Pneumocystis</i> pneumonia; SD = standard deviation.</p

Characteristics of HIV-infected subjects according to respiratory symptoms.

<p>Note: BP = bacterial pneumonia; CI = confidence interval; HAART = highly active antiretroviral therapy; IDU = intravenous drug use; MSM = men who have sex with men; OR = odds ratio; PCP = <i>Pneumocystis</i> pneumonia; SD = standard deviation.</p>*<p>per year.</p><p> ̂per 0.01 decrease.</p>¶<p>Odds ratio as compared to never smokers.</p

Prevalence of respiratory symptoms in HIV-infected subjects according to smoking history.

<p>Current/former smokers shown in black, never smokers in white. Dyspnea = dyspnea on exertion, shortness of breath = shortness of breath at rest. ^*p = 0.001; ^‡p = 0.01; ^†p<0.001.</p

Primary reason for not taking medications to prevent <i>Pneumocystis jirovecii</i> pneumonia (PCP) listed by 264 persons who were nonadherent with primary PCP prophylaxis – Supplement to HIV/AIDS Surveillance (SHAS) project, 2000–2004.

<p>Primary reason for not taking medications to prevent <i>Pneumocystis jirovecii</i> pneumonia (PCP) listed by 264 persons who were nonadherent with primary PCP prophylaxis – Supplement to HIV/AIDS Surveillance (SHAS) project, 2000–2004.</p

Characteristics of 1,666 persons with HIV infection prescribed primary prophylaxis against <i>Pneumocystis jirovecii</i> pneumonia (PCP), by nonadherence to prophylaxis – Supplement to HIV/AIDS Surveillance (SHAS) project, 2000–2004.

*<p>Column percentages may not total 100% because of rounding.</p>†<p>P-value <0.05 when comparing persons nonadherent with those adherent to PCP prophylaxis.</p>‡<p>Regions defined by U.S. Census Bureau; for SHAS sites included in this analysis, Northeast comprises NJ, CT, and PA; South comprises GA, MD, FL, SC, DE, and TX; Midwest comprises IL, KS, MI, and MN; and West comprises AZ, CA, CO, NM, and WA.</p>±<p>Other responses included correctional institution, refused to answer, and other responses which did not fit into the listed response categories.</p>§<p>Categories are mutually exclusive.</p>||<p>Defined as answering yes to at least 2 of the CAGE screening questions and reporting alcohol use in the past year.</p

Multivariable analysis of factors associated with nonadherence to primary prophylaxis against <i>Pneumocystis jirovecii</i> pneumonia (PCP) – Supplement to HIV/AIDS Surveillance (SHAS) project, 2000–2004.

*<p>In addition to adjusting for variables included in this table, we controlled for region of residence in the U.S. and year of SHAS interview.</p>†<p>P-value<0.05.</p

Additional file 1: of Measuring associations between the microbiota and repeated measures of continuous clinical variables using a lasso-penalized generalized linear mixed model

Table S1. Correlations between bacteria and laboratory measurements in OC-COPD. Table displays the Spearman correlations between all bacteria-laboratory measurement pairs. P values were adjusted (AdjustedP) using the Bonferroni correction. The last column (NwithGenus) is a count of the number of samples that contained the genus in that correlation-pair. (XLSX 173 kb

Additional file 3: of Measuring associations between the microbiota and repeated measures of continuous clinical variables using a lasso-penalized generalized linear mixed model

Table S2. Correlations between bacteria or fungi and cytokines in LHMP. Table displays the Spearman correlations between all bacteria/fungi-cytokine pairs. P values were adjusted (AdjustedP) using the Bonferroni correction. The last column (NwithGenus) is a count of the number of samples that contained the genus in that correlation-pair. (XLSX 161 kb

30-day vital status for patients with each clinical predictor score.

<p>p <0.0001 for the difference in mortality across clinical predictor score values.</p